Cartesian Therapeutics (Cartesian Therapeutics) Operating Cash Flow per Share : $-11.06 (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Operating Cash Flow per Share?

Cartesian Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was $-2.94. Cartesian Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Cartesian Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

During the past 10 years, Cartesian Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.30% per year. The lowest was -37.20% per year. And the median was 15.60% per year.

RNAC's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.55
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Cartesian Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Cartesian Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Operating Cash Flow per Share Chart

Cartesian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-33.88

10.34

-15.84

-6.51

-9.90

Cartesian Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-1.72	-1.94	-1.79	-4.40	-2.94

Competitive Comparison of Cartesian Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Cartesian Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cartesian Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Price-to-Operating-Cash-Flow falls into.

Cartesian Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Cartesian Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-51.161	/	5.170
	=	-9.90

Cartesian Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-15.917	/	5.414
	=	-2.94

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.06

Cartesian Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

1S7:Germany

Address

65 Grove Street, Watertown, MA, USA, 02472

Website

https://www.selectabio.com

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Executives

Carsten Brunn	director, officer: President & CEO	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber	officer: Chief Medical Officer	430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto	officer: Chief Scientific Officer	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston	officer: COO and SVP, R&D	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer	director	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan	officer: Chief Financial Officer	20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva	director	11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue	officer: VP Finance	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando	director
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan	officer: General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065